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Abstract
Antibody detection is a safely applied method at the wide scale in diagnosis of visceral Leishmaniasis (VL). In order to further
advance serodiagnosis, the rK28 antigen has been recently introduced as a candidate for diagnosis of VL. We evaluated the sensitivity
and speciﬁcity of the rK28 antigen in a micro-ELISA format in comparison to the rk39 antigen. The test was conducted on 252 para-
sitologically conﬁrmed VL cases, 103 endemic healthy controls, 95 non-endemic healthy controls, 88 other infectious disease and 53
follow-up cases. Of 252 parasitologically conﬁrmed VL cases, 251 cases were reported positive by rK28 antigen, yielding 99.6% sensi-
tivity (95% CI, 0.97–0.99), which was similar to the sensitivity of rK39 ELISA (99.6%) (95% CI, 0.97–0.99). Speciﬁcity of the rK28
antigen in non-endemic and endemic healthy controls was 100% (95% CI 0.96–1) and 94.17% (95% CI, 0.88–0.97), respectively. In 88
different diseases, speciﬁcity was 95.45% (95% CI, 0.84–0.96). With the rK39 antigen, speciﬁcity of non-endemic and endemic con-
trols and different diseases was 100% (95% CI 0.96–1), 92.23% (95% CI 0.85–0.96) and 96.59% (95% CI 0.90–0.98), respectively. Our
results show that rK39 and rK28 antigens have similar sensitivity and speciﬁcity and rK28 can also be used as a serodiagnostic tool
in the endemic population of Bihar.
Keywords: ELISA, rk-28, serodiagnosis, visceral Leishmaniasis
Original Submission: 3 January 2011; Revised Submission: 17 March 2011; Accepted: 22 March 2011
Editor: G. Greub
Article published online: 5 April 2011
Clin Microbiol Infect 2012; 18: 81–85
10.1111/j.1469-0691.2011.03540.x
Corresponding author: S. Sundar, Department of Medicine,
Institute of Medical Sciences, Banaras Hindu University, Varanasi –
221005, India
E-mail: drshyamsundar@hotmail.com
Introduction
Visceral Leishmaniasis (VL) is commonly known as kala-azar
in endemic areas of the Indian subcontinent, where deﬁni-
tive diagnosis and treatment still need attention. The dem-
onstration of amastigotes in splenic and/or bone marrow
aspirates remains the reference standard for accurate and
deﬁnitive diagnosis of VL. Though this procedure is most
speciﬁc its sensitivity widely depends on smear preparation,
proper staining and appropriate working of the microscope
[1]. Spleen aspirates are risky, and therefore require
technical expertise. Serodiagnosis based on IFA, Western
blot, DAT and ELISA are poorly adapted in the ﬁeld condi-
tions of an endemic region. Immunochromatographic tests
(ICT) are ready to use and require low maintenance in ﬁeld
settings. In the current scenario, the rK39 ICT assay is used
as a reference standard for the diagnosis of VL but its
inability to discriminate between clinical and subclinical
infection in an endemic population drew our attention
towards more speciﬁc and sensitive novel antigens. Many
other L. donovani-speciﬁc antigens have been characterized,
demonstrating variable speciﬁcity and sensitivity [2,3]. rK9,
rK26, rKRP42 and other antigens have been largely evalu-
ated on symptomatic VL of endemic populations but the
diagnostic accuracy of the rK39 antigen is the strongest
worldwide [4]. The sensitivity of the rK26 antigen
developed from Leishmania chagasi is only 20–40% in India
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[5,6]. The K9 antigen, which possesses 11 copies of a
14-amino-acid repeat in the open reading frame of K26 [5],
yields only 78% sensitivity [7]. Important drawbacks of rK39
in any format are its low sensitivity in Africa [8–10], which
to some extent has improved with the rapid tests manufac-
tured by DiaMed Cressier sur Morat (Switzerland), and a
large proportion (up to 32%) of asymptomatic healthy indi-
viduals from an endemic area testing positive [11]. Thus to
resolve these drawbacks, a new-generation fusion antigen
rK28 has been designed, which can perform better [12].
K28 is a recombinant synthetic gene of the kinesin region,
consisting of multiple tandem repeat sequences of the
L. donovani haspb1 and k39 kinesin genes to the complete
open reading frame of haspb2, increasing antigen epitope
density [12]. Though rK28 RDT has shown improved per-
formance in Sudan [12], its evaluation in the Indian subcon-
tinent is yet to be carried out. Thus the aim of this study
is to evaluate the diagnostic accuracy of the novel rK28
antigen in the endemic population of Bihar.
Materials and Methods
This prospective study was conducted at the Department of
Medicine, Institute of Medical Sciences, Banaras Hindu Uni-
versity, and at its ﬁeld site at Kala-azar Medical Research
Centre, Muzaffarpur, Bihar. The study was approved by the
ethical committee of the Institute of Medical Sciences, BHU
and KAMRC, Muzaffarpur. Written informed consent was
obtained from all subjects.
In this study, 591 subjects were enrolled during January 2010
to August 2010, including 252 parasitologically conﬁrmed
patients with VL, 103 endemic healthy controls (EHC) selected
from the VL endemic region of Muzaffarpur, and 95 non-ende-
mic healthy controls from Varanasi. All these individuals had no
past history of Kala-azar. In a panel of 88 other diseases, there
were patients with malaria (n = 15), tuberculosis (n = 10),
amoebic liver abscess (n = 17), dengue fever (n = 15), leprosy
(n = 15) and typhoid (n = 16). These subjects were recruited
and treated at SS Hospital, Banaras Hindu University, Varanasi.
Patients who were below the age of 2 years, had a past history
of kala-azar, or had positive HIV serology or positive pregnancy
tests, were excluded. The median age of patients was 25 years.
Among the recruited patients, 48% subjects were male and 52%
were female.
Serum sample collection
Serum was collected from patients with VL before the onset
of treatment. Serum was separated from 1 mL of blood col-
lected from different groups of controls and conﬁrmed VL
patients in cryovials and stored at )20C. The rK39 antigen
was used as a comparator in this study.
ELISA
rK28 and rK39 antigens were received as a kind gift from
S. G. Reed, Seattle, USA. ELISA was carried out as described
earlier [13]. Brieﬂy, ﬂat-bottom 96-well microtitre plates
were coated with 25 ng/well (100lL) of rK28 and rK39 anti-
gen in coating buffer and incubated overnight at 4C. The
plates were then blocked with blocking buffer (1% BSA in
0.05 M phosphate buffer) for 2 h at room temperature. Plates
were loaded with serum sample diluted 1:400 and incubated
at room temperature for 1 h. The plates were washed ﬁve
times with PBS containing 0.1% Tween-20 (pH 7.4) and incu-
bated with peroxidase-conjugated goat anti-human IgG (1:
32 000 dilution in serum dilution buffer) at 37C for 1 h.
Then the plates were incubated with TMB substrate
(GeNei) for 5 min at room temperature in the dark.
Finally, the reaction was stopped with 0.1 N H2SO4.
The optical density was measured at 450 nm. Each sample
was assayed in duplicate. Serum pools of pretreated VL
patients were used as a positive control and pooled non-
endemic controls were used as a negative control in each
plate.
Statistical analysis
Determination of sample size for the evaluation of the new
antigen rK28 in an endemic population was carried out by
McNemar’s test. The cut-off values for anti-rK39 antibodies
were set as the mean plus three standard deviations of the
healthy non-endemic controls. The serological data thus
obtained were analysed with EPIInfo (version-6) and SPSS 16
softwares. The generated predicted values were used to
construct a receiver-operator characteristic (ROC) curve
that plots the true-positive rate against the false-positive rate
for different potential cut-off points [14]. Data from the
repeatability experiment were used to estimate the kappa
value for the ELISA method for both the antigens. The kappa
coefﬁcient of agreement quantiﬁes reproducibility, correcting
for agreement expected by chance. A kappa value of 1 rep-
resents perfect agreement.
Results
The pool of sera from VL patients was serially diluted from
100 to 4 · 105 times to ﬁnd out the baseline of reactivity of
anti-rK39 antibodies and anti-rK28 antibody responses with
their respective antigens. Optical density at 4 · 105 dilution
lies just above the cut-off range of non-endemic healthy
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controls. 1:400 dilution of serum from a parasitologically
conﬁrmed VL patient reacted strongly with rK28 antigens at
a concentration as low as 25 ng/well.
To determine the serodiagnostic performance of the rK28
antigen, sensitivity and speciﬁcity of rK28 ELISA was com-
pared with sensitivity and speciﬁcity of rK39 ELISA. In symp-
tomatic VL cases, the mean titre of antibodies against rK28
and rK39 is 31 times higher than the mean titre of non-
endemic controls (Fig. 1).
Of 252 VL patients, 251 were positive by the rK28 anti-
gen, yielding sensitivity of 99.6%, which was exactly similar to
the sensitivity of rK39 ELISA (99.6%) (Table 1). There was
excellent agreement between the assays (kappa 0.97,
p <0.001) for serodiagnosis. The data for speciﬁcity are given
in Table 2. The speciﬁcity for rk28 was very high in all
groups, being 100% in non-endemic controls, and 94.17%
and 95.45% for endemic controls and different diseases
(Table 2). The data were comparable between rK28 and
rK39.
The area under the curve of the ROC plot by both the
antigens was 0.995, which shows the excellent performance
and diagnostic accuracy of rK28 and rK39 antigens.
For 53 patients with VL, sera at 6 month follow-up were
also available. There were 3.6- and 2.98-fold declines in the
titre of antibodies against rK28 and rK39 antigens, respec-
tively (Fig. 2). However, no signiﬁcant decline in titres was
observed at day 30 (p >0.05) in both antigens. Five out
of eight relapse cases showed the same value of anti-
body titre persisting till 6 months of follow-up. In the
remaining 45 cases, only four had no signiﬁcant decrease in
antibody titre.
Discussion
In this study, the sensitivity of the rK28 antigen was excellent
as out of 252 only one was negative in symptomatic VL
cases. The only rK28 antigen-negative patient was positive
with rK39 though the OD was low for this patient. VL sera
with borderline/low ELISA reactivity against the rK39 antigen
could be detected with similar accuracy with the rK28 anti-
gen. This can be clearly demonstrated by the fact that there
was no signiﬁcant difference between mean optical densities
of ELISA against both the antigens in the case of VL. Hence
sensitivity of rK28 was similar (99.6%) to the rK39 antigen.
The area under the ROC curve also shows excellent diag-
4
5
R
ea
ct
iv
ity
(op
tic
al 
de
ns
ity
 at
 45
0 n
m)
3
2
1
0
VL
EH
C
NE
HC DD V
L
EH
C
NE
HC DD
4
5
R
ea
ct
iv
ity
(op
tic
al 
de
ns
ity
 at
 45
0 n
m)
3
2
1
0
rK39 antigen rK28 antigen
p < 0.0001
Subject group Subject group
***
***
***
p < 0.0001
***
***
***
FIG. 1 Anti-rK39 and anti-rK28 antibody lev-
els in serum determined by ELISA in parasito-
logically conﬁrmed cases (VL) and three
groups of controls: non-endemic healthy
(NEHC), endemic healthy (EHC) and different
diseases (DD). Results are expressed as opti-
cal density at 450 nm. Dotted line represents
cut-off values between cases and control
groups. Each dot represents an individual sub-
ject, bars display median value.
TABLE 1. Comparative performance of rK39 and rK28 anti-
gens in visceral Leishmaniasis patients
Subjects,
VL (n = 252)
rK39 antigen rK28 antigen
KappaPositive (%) 95% CI Positive (%) 95% CI
251 (99.6%) 97.3–99.9 251 (99.6%) 97.3–99.9 0.97
TABLE 2. Comparative speciﬁcity of rK39 and rK28 anti-
gens in different control groups
Subjects
rK39 antigen rK28 antigen
KappaNegative (%) 95% CI Negative (%) 95% CI
Endemic healthy
(n = 103)
95 (92.2) 0.85–0.96 97 (94.2) 0.87–0.97 0.86
Non-endemic
healthy (n = 95)
95 (100) 0.96–1.0 95 (100) 0.96–1.0 1
Different diseases
(n = 88)
85 (96.6) 0.90–0.98 84 (95.5) 0.84–0.96 0.86
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nostic accuracy for the rK28 antigen, which was similar to
the rK39 antigen. Speciﬁcity of the rK28 antigens was slightly
higher (approximately 2%) than for the rK39 antigens for
healthy subjects from the endemic population. In a panel of
patients with different diseases, all 15 malaria patients were
negative and one tuberculosis patient was positive with
rK39. The situation was the opposite for the rK28 antigen
(i.e. one was positive in the malaria group and all were nega-
tive in the tuberculosis group). No subjects were positive in
the group of patients suffering from dengue fever and lep-
rosy, while one individual was positive in the typhoid group
with both the antigens. In a group with amoebic liver
abscesses, one subject was positive with rk39 and two were
positive by the rK28 antigen. Hence, there was only 4.5%
cross-reactivity with rK28, which was quite similar to the
rK39 antigen. Overall speciﬁcity in the control group against
both antigens was quite similar (>94%) and agreement
between both assays was also excellent (Kappa 0.86).
In 53 follow-up cases, there was a similar decrease in anti-
body level at follow-up with both the antigens, though the ti-
tres remained high with both antigens. Thus we can
conclude that the synthetic new-generation rK28 antigen
shows excellent sensitivity and speciﬁcity, similar to the rK39
antigen in ELISA format, and is an additional tool in the
armamentarium for VL diagnosis.
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